Let’s look at the key reasons that are pushing Aytu BioPharma Inc (AYTU) to new highs

Aytu BioPharma Inc (NASDAQ: AYTU) on Monday, soared 3.81% from the previous trading day, before settling in for the closing price of $2.1. Within the past 52 weeks, AYTU’s price has moved between $0.95 and $2.96.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


Sponsored

Healthcare Sector giant saw their annual sales surged by 66.68% over the last five years. The company achieved an average annual earnings per share of 108.04%. With a float of $5.40 million, this company’s outstanding shares have now reached $6.17 million.

The firm has a total of 102 workers. Let’s measure their productivity. In terms of profitability, gross margin is 68.59%, operating margin of -5.57%, and the pretax margin is 2.57%.

Aytu BioPharma Inc (AYTU) Breakdown of a Key Holders of the stock

Observing investor behavior towards Drug Manufacturers – Specialty & Generic industry stocks is more important than anything else. The insider ownership of Aytu BioPharma Inc is 12.52%, while institutional ownership is 39.71%. The most recent insider transaction that took place on Jun 09 ’25, was worth 24,999. In this transaction Chief Business Officer of this company bought 16,666 shares at a rate of $1.50, taking the stock ownership to the 29,462 shares. Before that another transaction happened on Jun 09 ’25, when Company’s Chief Executive Officer bought 66,666 for $1.50, making the entire transaction worth $99,999. This insider now owns 153,257 shares in total.

Aytu BioPharma Inc (AYTU) Recent Fiscal highlights

Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.3 per share during the current fiscal year.

According to the Wall Street analysts, stocks earnings will be around 108.04% per share during the next fiscal year.

Aytu BioPharma Inc (NASDAQ: AYTU) Trading Performance Indicators

Aytu BioPharma Inc (AYTU) is currently performing well based on its current performance indicators. A quick ratio of 0.87 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 0.19.

For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.71, a number that is poised to hit -0.02 in the next quarter and is forecasted to reach -0.15 in one year’s time.

Technical Analysis of Aytu BioPharma Inc (AYTU)

Analysing the last 5-days average volume posted by the [Aytu BioPharma Inc, AYTU], we can find that recorded value of 0.33 million was lower than the volume posted last year of 0.74 million. As of the previous 9 days, the stock’s Stochastic %D was 69.85%.

During the past 100 days, Aytu BioPharma Inc’s (AYTU) raw stochastic average was set at 70.29%, which indicates a significant increase from 56.86% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 42.25% in the past 14 days, which was lower than the 133.68% volatility it showed in the past 100 days.

At the time of writing, stock’s 50-day Moving Average is $1.67, while its 200-day Moving Average is $1.68. Now, the first resistance to watch is $2.36. This is followed by the second major resistance level at $2.53. The third major resistance level sits at $2.67. If the price goes on to break the first support level at $2.05, it is likely to go to the next support level at $1.91. Now, if the price goes above the second support level, the third support stands at $1.74.

Aytu BioPharma Inc (NASDAQ: AYTU) Key Stats

Market capitalization of the company is 13.45 million based on 8,977K outstanding shares. Right now, sales total 81,000 K and income totals -15,840 K. The company made 18,450 K in profit during its latest quarter, and 3,990 K in sales during its previous quarter.

News Daemon
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.